Summary of ResMed Inc. (NYSE:RMD) Ratings as of May 3, 2018

May 3, 2018 - By Jeanette Garcia

ResMed Inc. (NYSE:RMD) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.51. That’s change of 0.16, from 2017Q3’s 1.35. 19 investors sold all, 99 reduced holdings as ResMed Inc. ratio improved. 118 rose holdings while 60 funds bought holdings. Funds hold 86.81 million shares thus 0.12% more from 2017Q3’s 86.71 million shares.
Moreover, Teachers Retirement Of The State Of Kentucky has 0.02% invested in ResMed Inc. (NYSE:RMD). Stone Ridge Asset Mngmt Limited Liability Company, New York-based fund reported 6,301 shs. Ameriprise Inc stated it has 0% of its capital in ResMed Inc. (NYSE:RMD). Bessemer Group Incorporated stated it has 0% of its capital in ResMed Inc. (NYSE:RMD). Westpac Corporation has invested 0.02% of its capital in ResMed Inc. (NYSE:RMD). Deutsche Natl Bank Ag owns 204,634 shs or 0.01% of their US capital. Amp Cap reported 37,674 shs. Toronto Dominion State Bank owns 61,142 shs or 0.02% of their US capital. Robeco Institutional Asset Mngmt Bv reported 0% of its capital in ResMed Inc. (NYSE:RMD). Td Asset Management has 0.01% invested in ResMed Inc. (NYSE:RMD). Tru Department Mb Commercial Bank N A stated it has 400 shs or 0% of all its holdings. West Coast Fincl Ltd Liability Com has invested 1.95% in ResMed Inc. (NYSE:RMD). Advisory Svcs Net Ltd Liability Corp reported 0% stake. State Of Alaska Department Of Revenue accumulated 31,339 shs. 14,533 were reported by Advantus Cap Mngmt Inc.

ResMed Inc. had 17 selling transactions and 0 insider buys since January 2, 2018. This’s net activity of $5.48 million. Sandercock Brett sold $198,720 worth of stock or 2,000 shs. 25,934 shs were sold by WAREHAM JOHN P, worth $2.65M. On Wednesday, January 24 TAYLOR RONALD R sold $487,083 worth of ResMed Inc. (NYSE:RMD). PENDARVIS DAVID sold $269,844 worth of ResMed Inc. (NYSE:RMD) or 2,810 shs on Monday, February 5. 2,000 shs were sold by McHale Richard, worth $200,240.

ResMed Inc. (NYSE:RMD) Ratings Coverage

Total analysts of 4 have positions in ResMed (NYSE:RMD) as follows: 0 rated it a “Buy”, 1 with “Sell” and 3 with “Hold”. The positive are 0. Since January 23, 2018 according to StockzIntelligence Inc ResMed has 4 analyst reports. On Tuesday, January 23 the rating was upgraded by Northland Capital to “Hold”. On Wednesday, April 4 the company was downgraded by Citigroup. On Tuesday, January 23 the rating was upgraded by Needham to “Hold”. On Tuesday, January 23 the firm earned “Sell” rating by Macquarie Research. Listed here are ResMed Inc. (NYSE:RMD) PTs and latest ratings.

04/04/2018 Broker: Citigroup Old Rating: Buy New Rating: Neutral Downgrade
23/01/2018 Broker: Macquarie Research Rating: Sell Downgrade
23/01/2018 Broker: Northland Capital Rating: Hold Upgrade
23/01/2018 Broker: Needham Old Rating: Underperform New Rating: Hold Upgrade

The stock increased 0.74% or $0.7 during the last trading session, touching $95.82.ResMed Inc. has 932,506 shares volume, 42.29% up from normal. RMD is uptrending and has moved 35.71% since May 3, 2017. RMD outperformed the S&P500 by 24.16%.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases.The company has $13.68 billion market cap. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud software informatics solutions to manage patient outcomes, as well as provides customer and business processes.48.22 is the P/E ratio. The firm also provides humidifiers, carry bags, and breathing circuits; and data communications and control products, such as EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators.

ResMed Inc. (NYSE:RMD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.